

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hodge et al.

Application No. 10/535,523

Filed: May 17, 2005

Confirmation No. 8826

For: CELL LINES AND HOST NUCLEIC ACID
SEQUENCES RELATED TO INFECTIOUS
DISEASE

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 6395-66741-06

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)

Date Mailed September 2, 2005

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith is an English-language document. Applicants respectfully request that this document be listed as a reference cited on the issued patent.


Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.


Respectfully submitted,


KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

cc: Docketing





INFORMATION DISCLOSURE STATEMENT BY APPLICANT

| | |
|------------------------|------------------|
| Attorney Docket Number | 6395-66741-06 |
| Application Number | 10/535,523 |
| Filing Date | May 17, 2005 |
| First Named Inventor | Hodge |
| Art Unit | Not yet assigned |
| Examiner Name | Not yet assigned |

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

| Examiner's Initials* | Cite No. (optional) | Number | Publication Date | Name of Applicant or Patentee |
|----------------------|---------------------|--------|------------------|-------------------------------|
| | | | | |
| | | | | |
| | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials* | Cite No. (optional) | Country | Number | Publication Date | Name of Applicant or Patentee |
|----------------------|---------------------|---------|--------|------------------|-------------------------------|
| | | | | | |
| | | | | | |
| | | | | | |

OTHER DOCUMENTS

| Examiner's Initials* | Cite No. (optional) | |
|----------------------|---------------------|--|
| | | DesJarlais et al., "A Shape- and Chemistry-Based Docking Method and Its Use in the Design of HIV-1 Protease Inhibitors," <i>J. Comput. Aided Mol. Des.</i> 8:231-242 (1994). |
| | | |
| | | |
| | | |
| | | |
| | | |

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.